PARTNERS & CEO

Antonio Llombart LinkedIN

MARIA

CAMPOS

Founding

Partner

Maria Campos LinkedIN

ANTONIO

LLOMBART

Founding

Partner

Dr. Antonio Llombart MD, PhD is Chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain and founding partner of Medica Scientia Innovation Research (MedSIR).

He received his medical training in Pamplona and Valencia, finalizing a Medical Oncology degree from the University Hospital in Valencia. After his fellowship period (1994 to 1997) in the Breast Cancer Unit at Institute Gustave Roussy (Villejuif, France) focusing on new drugs (phase I and II studies), he became a medical staff member for two years in this french institution. Upon his return to Valencia, he chaired the Breast Cancer Research Unit at the Instituto Valenciano de Oncologia and, later, at the Medical Oncology Service of the University Hospital Arnau de Vilanova in Lleida, Spain, with a multidisciplinary scientific clinical unit made up of pharmacologists, surgeons, pathologists and biologists working with cytotoxic and molecular agents both in human and animal models. His main current focus is on translational clinical trials and correlative science in the neoadjuvant management of breast cancer patients.

He is an active member of the Spanish and European clinical oncology community, working together with many international co-operative groups (BIG, GEICAM, SOLTI) and designing innovative clinical trials. He is also a Board Member of the Spanish Society of Medical Oncology.

Antonio is also en expert consultant for several pharmaceutical companies (Eli Lilly, Novartis, Pfizer Oncology and Boehringer Ingelheim, Pierre Fabre) as well as the Institut National du Cancer (INCA), Paris, France. His contributions, as a member of the International Scientific Committee, in several pivotal international studies in breast cancer (P024, ZO-FAST) have helped to develop new drugs and, also, new therapeutical strategies.

He is a member of Editorial Board of the journal Oncologie, La revue francophone de formation en Oncologie and author of more than 70 peer-reviewed publications.

 
 

Maria Campos earned her undergraduate degree in Pharmacy at the University of Barcelona followed by a Degree in Quality Assurance from the American Society
of Quality Control and since then began her career of now more than 20 years in
the Clinical Research field.

Maria has spent the bulk of the last two decades in the Oncology field in both US
and European Pharmaceutical Companies, with the majority of her time spent in solid tumors (lung and breast cancer) and in liquid tumors such as Non-Hodgkin’s disease and Myeloma.

Over these years Maria developed a strong interest for the development of pharmacological treatments with a special focus on the optimization and innovation
of traditional drug developmental processes in order to help increase efficiency and success rates of new molecules in the “fight against cancer”. In 2012, with this goal
and dream in mind, Maria helped found, together with experts in Oncology, the company called Medica Scientia Innovation Research (MedSIR) and currently holds
the position of Scientific Director.

Maria is very well-travelled and speaks Catalan, Spanish and English fluently and has working knowledge of French.


 

 

JAVIER

CORTES

Founding

Partner

Javier Cortés LinkedIN

Head, Breast Cancer Program, IOB Insititute of Oncology, Madrid and Barcelona, SP.

 

Clinical Investigator, Breast Cancer Research Program Vall d’Hebron Institute of Oncology, Barcelona, SP.

Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr. Cortes was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr. Cortes was the Head of the Breast Cancer Program and the Melanoma Unit from July 2006 to August 2015. From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. He is Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology, and Head of Breast Cancer Program, IOB Institute of Oncology, Madrid and Barcelona, Spain.

In addition to his medical specialties, he has two masters’ degree in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.

Dr. Cortes is the author of more than 240 publications, especially about breast tumours and new drugs and more than 500 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.

Dr. Cortes is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), American Association for Cancer research (AACR) and a member of the Scientific Committee of the European Society of Medical Oncology.

Top 10 publications over the last 3 years:
• Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016 Sep 22;167(1):260-274.

• Llombart-Cussac A, Cortes J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A.; HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr;18(4):545-554.

• Baselga J, Im SA, Iwata H, Cortes J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):904-916.

• Méndez-Pertuz M, Martñinez P, Blanco-Aparicio C, Gómez-Casero E, García AB, Martínez-Torrecuadrada J, Palafox M, Cortes J, Serra V, Pastor J, Blasco MA. Modulation of telomere protection by the PI3K/AKT pathway. Nat Commun 2017 Nov 2;8(1):1278.

• Perez García J, Cortes J. Breast cancer in 2017: Spurring science, marking progress, and influencing history. Nat Rev Clin Oncol. 2018 Feb;15(2):79-80.